U.S. Markets closed

4D pharma plc (LBPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.21-0.07 (-0.75%)
At close: 1:46PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.28
Open9.22
Bid9.19 x 1300
Ask9.49 x 1400
Day's Range9.18 - 9.36
52 Week Range8.97 - 15.50
Volume7,817
Avg. Volume16,941
Market Cap210.46M
Beta (5Y Monthly)2.81
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T

    LEEDS, England, July 06, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the publication of pre-clinical research relating to its second-generation immuno-oncology LBP MRx1299 improving the activity of CAR-T.

  • Business Wire

    4D pharma to Participate in Ladenburg Thalmann Healthcare Conference

    LEEDS, England, June 29, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer, will present a corporate overview followed by a fireside chat at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021, at 2:30pm ET (7:30pm BST).

  • Business Wire

    4D pharma to Present at the Microbiome Movement Drug Development Summit

    LEEDS, England, Jun 22, 2021--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces Christophe Carite, Development Director, will deliver a presentation on 4D pharma’s strategy and capabilities for the manufacturing of its Live Biotherapeutic drug candidates at the upcoming virtual Microbiome Movement Drug Development Summit, on Thursday, July 1 at 2.15p